Trevi Therapeutics, Inc. TRVI
Trevi Therapeutics, Inc. (Nasdaq: TRVI) is a respiratory drug developer. Its lead program, Haduvio (oral nalbuphine ER), is in Phase 3 for Chronic cough in idiopathic pulmonary fibrosis (IPF). Its next catalyst on record is Haduvio: Phase 2b LAKE sample size re-estimation (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Haduvio — Phase 2b LAKE sample size re-estimation (Q4 2026). 5 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Haduvio (oral nalbuphine ER) | IPF-related chronic cough | small molecule | OCEAN-2 topline 2027-H2; OCEAN-1 topline 2028-H1 |
| Haduvio | Refractory chronic cough (RCC) | small molecule | Phase 2b LAKE topline 2027-H2 |
| Haduvio | Non-IPF ILD chronic cough | small molecule | Phase 2b start 2026-H2; topline 2027-H2 |
Recent results and decisions
- Aug 6, 2026started Phase 3 OCEAN-1 (52-week fixed dosing) initiated in Q2 2026; topline expected 1H 2028.
The Company initiated the Phase 3 OCEAN-1 trial, the first of two parallel conducted Phase 3 trials in patients with IPF-related chronic cough, in the second quarter of 2026.
Filing - Mar 17, 2026positive Company reports overall alignment with FDA at End-of-Phase 2 meeting on two pivotal Phase 3 trials and remaining Phase 1 studies for NDA.
The Company had its End-of-Phase 2 meeting with the FDA and gained overall alignment on the plan for the remaining development program of nalbuphine ER (NAL ER) for the treatment of IPF-related chronic cough.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 respiratory companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.